Log in

CVE:LBLLattice Biologics Stock Price, Forecast & News

-0.01 (-10.00 %)
(As of 06/4/2020 05:02 AM ET)
Today's Range
Now: C$0.05
50-Day Range
MA: C$0.09
52-Week Range
Now: C$0.05
Volume41,250 shs
Average Volume1.98 million shs
Market CapitalizationC$4.21 million
P/E RatioN/A
Dividend YieldN/A
Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic allograft products for use in the field of cellular therapies and tissue engineering with a focus on bone, skin, and cartilage regeneration worldwide. The company offers AmnioBoost, an allograft amniotic fluid visco supplement for the treatment of joint pain associated with osteoarthritis, as well as traditional, spinal, particulate, soft tissue, dental, membrane and barrier, and demineralized bone matrix allografts. Its products are used in a range of applications, including enhancing fusion in spine surgery and breast reconstruction post mastectomy, promotion of bone regeneration in foot and ankle surgery, promotion of skull healing following neurosurgery, enhancing wound repair in burn victims, and subchondral bone defect repair in knee and other joint surgeries, as well as sports medicine indications, such as anterior cruciate ligament repair. The company is headquartered in Belgrade, Montana.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.54 out of 5 stars

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic



Sales & Book Value

Annual SalesC$2.42 million
Book ValueC($0.07) per share



Market CapC$4.21 million
Next Earnings Date9/3/2020 (Estimated)
OptionableNot Optionable

Receive LBL News and Ratings via Email

Sign-up to receive the latest news and ratings for LBL and its competitors with MarketBeat's FREE daily newsletter.

Lattice Biologics (CVE:LBL) Frequently Asked Questions

How has Lattice Biologics' stock been impacted by COVID-19 (Coronavirus)?

Lattice Biologics' stock was trading at C$0.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, LBL shares have increased by 50.0% and is now trading at C$0.05. View which stocks have been most impacted by Coronavirus.

When is Lattice Biologics' next earnings date?

Lattice Biologics is scheduled to release its next quarterly earnings announcement on Thursday, September 3rd 2020. View our earnings forecast for Lattice Biologics.

Has Lattice Biologics been receiving favorable news coverage?

Press coverage about LBL stock has been trending very negative this week, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Lattice Biologics earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutLattice Biologics.

Who are some of Lattice Biologics' key competitors?

What other stocks do shareholders of Lattice Biologics own?

Who are Lattice Biologics' key executives?

Lattice Biologics' management team includes the following people:
  • Mr. Guy S. Cook, CEO, Pres & Director (Age 54)

What is Lattice Biologics' stock symbol?

Lattice Biologics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "LBL."

How do I buy shares of Lattice Biologics?

Shares of LBL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Lattice Biologics' stock price today?

One share of LBL stock can currently be purchased for approximately C$0.05.

How big of a company is Lattice Biologics?

Lattice Biologics has a market capitalization of C$4.21 million and generates C$2.42 million in revenue each year.

What is Lattice Biologics' official website?

The official website for Lattice Biologics is www.latticebiologics.com.

How can I contact Lattice Biologics?

Lattice Biologics' mailing address is 16701 N 90th St Ste 101, SCOTTSDALE, AZ 85260-1012, United States. The company can be reached via phone at +1-604-2356701.

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.